Medicine's First Therapeutic Cancer Vaccine: The Challenge, the Breakthrough, & the Future

Commonly thought to be an impossible undertaking 18 years ago, learn how Dr. Engleman and his researchers were able to utilize one of the body's own infection fighters (a type of white blood cell known as a dendritic cell) to attack cancer. Provenge, the first commercially available vaccine to utilize this technology, was shown to extend the life of patients with end stage prostate cancer, thereby gaining FDA approval in April, 2010. Dr. Engleman will also share his latest dendritic cell research and his assessment of the future of cancer vaccines.

Speaker: Edgar Engleman, M.D., Professor of Pathology & Blood Center Director, Stanford University.